<DOC>
	<DOCNO>NCT01324440</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity Merck 0657nI S. aureus vaccine ( V710 ) either without Merck Aluminum Adjuvant ( MAA ) .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Single Dose Merck 0657nI Staphylococcus Aureus Vaccine With Without Merck Aluminum Adjuvant ( V710-002 )</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Participant good physical health Participant able understand study procedure agree participate study provide write informed consent . Participant willing able participate entire study duration plan 12 month ( ~360 day ) . Female participant reproductive potential require negative urine pregnancy test immediately prior study vaccination . Female participant reproductive potential must use acceptable method birth control 2 week prior enrollment , agree use acceptable method birth control 1 month vaccination . Exclusion criterion : Participant suffer chronic skin condition predispose individual development chronic skin softtissue infection ( e.g. , psoriasis , chronic granulomatous disease , atopic dermatitis ) . Participant develop serious infection ( e.g. , bacteremia , pneumonia , mediastinitis ) attribute S. aureus 12 month prior screen . Participant history anaphylaxis aluminumcontaining adjuvant vaccine component . Participant temperature ≥100.4ºF ( ≥38.0ºC ) , oral equivalent , within 48 hour prior receipt V710 . Participant receive live virus vaccine within 30 day prior receipt V710 schedule receive vaccination live virus vaccine within 30 day follow study entry . Participant receive licensed vaccine ( include nonlive virus vaccine ) within 14 day prior receipt V710 schedule receive license vaccine ( include nonlive virus vaccine ) within 30 day follow study entry . Participant receive V710 prior clinical study ( Merck V710 Protocol 001 ) . Participant administer immunoglobulin blood product within 90 day prior receipt V710 schedule receive product within 30 day follow study entry . Participant receive treatment systemic ( intramuscular , oral , intravenous ) corticosteroids another immunosuppressive medication ( e.g. , calcineurin inhibitor , mycophenolate , azathioprine ) biological agent ( e.g. , rituximab ) 14 day prior receipt V710 anticipate receive medication chronic medical condition course study . Participant condition require active medical intervention monitoring avert serious danger participant 's health wellbeing , diabetes mellitus , autoimmune disease , clinically significant chronic medical condition consider progressive , include limited : coronary artery disease , congestive heart failure , cardiomyopathy , progressive valvular heart disease , chronic obstructive pulmonary disease , pulmonary fibrosis , active peptic ulcer disease , chronic renal disease , chronic hepatic disease , multiple sclerosis , progressive neuropathy , seizure disorder require therapy past 3 year . Participant know suspect impairment immunologic function include , limited , following condition : autoimmune disease , diabetes mellitus , endstage renal disease , hepatic insufficiency/cirrhosis , splenectomy , human immunodeficiency virus/acquired immune deficiency syndrome ( HIV/AIDS ) . Participant condition repeat venipuncture injection pose minimal risk subject , hemophilia , severe coagulation disorder , significantly impaired venous access . Participant pregnant breastfeeding , plan conceive within 12month study duration period . Participant clinically significant abnormality base participant physical examination . Participant recent history ( within past 5 year ) current evidence drug alcohol abuse . Participant major psychiatric illness , include history schizophrenia severe psychosis , bipolar disorder require therapy , subject suicidal ideation within previous 3 year . Participant legally mentally incapacitate . Participant participate another clinical study past 4 week , participant plan participate treatmentbased study study invasive procedure perform first 3 month study ( Day 84 ) . Participant history condition , opinion investigator , pose additional risk subject confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bacterial Vaccines</keyword>
	<keyword>Staphylococcus Aureus</keyword>
	<keyword>Adjuvanted Vaccine</keyword>
</DOC>